JP2008502323A - コブラ毒因子様機能を有するヒト補体ｃ３誘導体 - Google Patents
コブラ毒因子様機能を有するヒト補体ｃ３誘導体 Download PDFInfo
- Publication number
- JP2008502323A JP2008502323A JP2007511077A JP2007511077A JP2008502323A JP 2008502323 A JP2008502323 A JP 2008502323A JP 2007511077 A JP2007511077 A JP 2007511077A JP 2007511077 A JP2007511077 A JP 2007511077A JP 2008502323 A JP2008502323 A JP 2008502323A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- modified
- cvf
- complement
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000901154 Homo sapiens Complement C3 Proteins 0.000 title claims abstract description 177
- 239000002642 cobra venom Substances 0.000 title description 3
- 101710172562 Cobra venom factor Proteins 0.000 claims abstract description 226
- 101710131943 40S ribosomal protein S3a Proteins 0.000 claims abstract description 102
- 102000057770 human C3 Human genes 0.000 claims abstract description 79
- 238000000034 method Methods 0.000 claims abstract description 69
- 201000010099 disease Diseases 0.000 claims abstract description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 36
- 230000024203 complement activation Effects 0.000 claims abstract description 34
- 238000006467 substitution reaction Methods 0.000 claims abstract description 29
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 16
- 238000001415 gene therapy Methods 0.000 claims abstract description 11
- 230000000295 complement effect Effects 0.000 claims description 87
- 108090000056 Complement factor B Proteins 0.000 claims description 72
- 102000003712 Complement factor B Human genes 0.000 claims description 55
- 150000001413 amino acids Chemical class 0.000 claims description 32
- 125000000539 amino acid group Chemical group 0.000 claims description 17
- 230000015572 biosynthetic process Effects 0.000 claims description 15
- 230000002163 immunogen Effects 0.000 claims description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 102000035118 modified proteins Human genes 0.000 claims description 11
- 108091005573 modified proteins Proteins 0.000 claims description 11
- 230000010410 reperfusion Effects 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 238000012384 transportation and delivery Methods 0.000 claims description 8
- 230000000779 depleting effect Effects 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 239000000032 diagnostic agent Substances 0.000 claims description 5
- 229940039227 diagnostic agent Drugs 0.000 claims description 5
- 230000017531 blood circulation Effects 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 150000007523 nucleic acids Chemical group 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 210000004204 blood vessel Anatomy 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 206010034277 Pemphigoid Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 230000002612 cardiopulmonary effect Effects 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 208000031225 myocardial ischemia Diseases 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 99
- 108090000623 proteins and genes Proteins 0.000 abstract description 99
- 230000000694 effects Effects 0.000 abstract description 71
- 230000006870 function Effects 0.000 abstract description 35
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 abstract description 34
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 abstract description 34
- 230000005847 immunogenicity Effects 0.000 abstract description 16
- 206010063837 Reperfusion injury Diseases 0.000 abstract description 12
- 230000002829 reductive effect Effects 0.000 abstract description 7
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 6
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 97
- 102100022133 Complement C3 Human genes 0.000 description 77
- 102000004190 Enzymes Human genes 0.000 description 54
- 108090000790 Enzymes Proteins 0.000 description 54
- 229940088598 enzyme Drugs 0.000 description 54
- 238000003776 cleavage reaction Methods 0.000 description 53
- 230000007017 scission Effects 0.000 description 52
- 238000006243 chemical reaction Methods 0.000 description 43
- 238000003556 assay Methods 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 37
- 210000002966 serum Anatomy 0.000 description 34
- 235000001014 amino acid Nutrition 0.000 description 32
- 238000001994 activation Methods 0.000 description 28
- 230000004913 activation Effects 0.000 description 25
- 230000027455 binding Effects 0.000 description 25
- 239000013612 plasmid Substances 0.000 description 25
- 230000035772 mutation Effects 0.000 description 22
- 239000012634 fragment Substances 0.000 description 20
- 102100034622 Complement factor B Human genes 0.000 description 18
- 108090000955 Complement C2 Proteins 0.000 description 17
- 108010053085 Complement Factor H Proteins 0.000 description 17
- 102000016550 Complement Factor H Human genes 0.000 description 17
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 17
- 239000000499 gel Substances 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 241000270295 Serpentes Species 0.000 description 15
- 238000011282 treatment Methods 0.000 description 13
- 230000003197 catalytic effect Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 9
- 230000000451 tissue damage Effects 0.000 description 9
- 231100000827 tissue damage Toxicity 0.000 description 9
- 239000003446 ligand Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000009885 systemic effect Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 230000002269 spontaneous effect Effects 0.000 description 7
- 241000700199 Cavia porcellus Species 0.000 description 6
- 208000017667 Chronic Disease Diseases 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 230000004154 complement system Effects 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 239000011777 magnesium Substances 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 5
- 238000012286 ELISA Assay Methods 0.000 description 5
- 230000002391 anti-complement effect Effects 0.000 description 5
- 108010008730 anticomplement Proteins 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 239000007795 chemical reaction product Substances 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 102000034356 gene-regulatory proteins Human genes 0.000 description 5
- 108091006104 gene-regulatory proteins Proteins 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 150000007970 thio esters Chemical class 0.000 description 5
- 108010089414 Anaphylatoxins Proteins 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 102000000989 Complement System Proteins Human genes 0.000 description 4
- 108010069112 Complement System Proteins Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000000981 bystander Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000007123 defense Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 230000008728 vascular permeability Effects 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 3
- 101000767763 Austrelaps superbus A.superbus venom factor 1 Proteins 0.000 description 3
- 101000767764 Austrelaps superbus A.superbus venom factor 2 Proteins 0.000 description 3
- 101000767761 Crotalus adamanteus Venom factor Proteins 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 101000767760 Ophiophagus hannah Ophiophagus venom factor Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000012160 loading buffer Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 101150071258 C3 gene Proteins 0.000 description 2
- 102000016918 Complement C3 Human genes 0.000 description 2
- 108010028780 Complement C3 Proteins 0.000 description 2
- 108010078015 Complement C3b Proteins 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 108700022810 Drosophila Hsc70-3 Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000737574 Homo sapiens Complement factor H Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 208000024781 Immune Complex disease Diseases 0.000 description 2
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 2
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102100038567 Properdin Human genes 0.000 description 2
- 108010005642 Properdin Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229930189065 blasticidin Natural products 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000001045 blue dye Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001142 circular dichroism spectrum Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000037029 cross reaction Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 102000045512 human CFH Human genes 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000002482 oligosaccharides Polymers 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- -1 α-galactosyl residues Chemical group 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
- 108010003529 Alternative Pathway Complement C3 Convertase Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 229940124073 Complement inhibitor Drugs 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 101100117236 Drosophila melanogaster speck gene Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000272060 Elapidae Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 101100328540 Homo sapiens C3 gene Proteins 0.000 description 1
- 101100440311 Homo sapiens C5 gene Proteins 0.000 description 1
- 241000235789 Hyperoartia Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 101100328548 Rattus norvegicus C3 gene Proteins 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 101100328546 Sus scrofa C3 gene Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 108010052926 complement C3d,g Proteins 0.000 description 1
- 239000004074 complement inhibitor Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000010397 one-hybrid screening Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- SBOVPVCZPCSOEQ-PMACEKPBSA-N tert-butyl N-[(2S)-1-[[2-[[(2S)-1-[3-(aminomethyl)-2-oxochromen-4-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound C1=CC=CC2=C1OC(=O)C(CN)=C2C(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@@H](NC(=O)OC(C)(C)C)CC(C)C SBOVPVCZPCSOEQ-PMACEKPBSA-N 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56706904P | 2004-04-30 | 2004-04-30 | |
| US65324705P | 2005-02-14 | 2005-02-14 | |
| US66735205P | 2005-03-31 | 2005-03-31 | |
| PCT/US2005/015119 WO2005107785A2 (en) | 2004-04-30 | 2005-04-29 | Human complement c3 derivates with cobra venom factor-like function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008502323A true JP2008502323A (ja) | 2008-01-31 |
| JP2008502323A5 JP2008502323A5 (enExample) | 2008-05-29 |
Family
ID=35320733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007511077A Pending JP2008502323A (ja) | 2004-04-30 | 2005-04-29 | コブラ毒因子様機能を有するヒト補体ｃ３誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8632780B2 (enExample) |
| EP (1) | EP1755658A4 (enExample) |
| JP (1) | JP2008502323A (enExample) |
| KR (1) | KR20070036057A (enExample) |
| AU (1) | AU2005240096A1 (enExample) |
| CA (1) | CA2565227A1 (enExample) |
| IL (1) | IL178905A0 (enExample) |
| MX (1) | MXPA06012321A (enExample) |
| WO (1) | WO2005107785A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017519049A (ja) * | 2014-06-12 | 2017-07-13 | ユニヴァーシティ オブ ハワイＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｈａｗａｉｉ | 免疫原性を低減するかまたは予防するためのヒト化コブラ毒因子の使用 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005003159A1 (en) | 2003-07-03 | 2005-01-13 | Koeln Johanna | Complement depletion using recombinant human c3-derivatives |
| US8632780B2 (en) | 2004-04-30 | 2014-01-21 | University Of Hawaii | Human complement C3 derivates with cobra venom factor-like function |
| WO2010056399A1 (en) * | 2008-11-17 | 2010-05-20 | Incode Biopharmaceutics, Inc. | Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors |
| RU2549468C2 (ru) * | 2013-08-09 | 2015-04-27 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт нормальной физиологии имени П.К. Анохина" Российской академии медицинских наук (ФГБУ "НИИНФ им. П.К. Анохина" РАМН") | Способ определения стабилизации с3-конвертазы классического пути активации комплемента человека |
| US20190016766A1 (en) * | 2015-10-07 | 2019-01-17 | Daniel E. Benjamin | Use of improved modulators of complement function as cancer therapeutics |
| US11903996B2 (en) * | 2015-10-07 | 2024-02-20 | David C. Fritzinger | Modulators of complement function |
| CN106472354B (zh) * | 2016-10-21 | 2019-05-31 | 新希望六和饲料股份有限公司 | 一种成年鸡用饲料盘 |
| CN106472359B (zh) * | 2016-10-21 | 2019-07-26 | 新希望六和饲料股份有限公司 | 一种1-3周龄雏鸡用饲料盘 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4661347A (en) * | 1982-11-12 | 1987-04-28 | Scripps Clinic | Cytotoxic compositions |
| CA2160127A1 (en) * | 1993-04-07 | 1994-10-13 | David C. Fritzinger | Dna encoding cobra c3, cvf1, and cvf2 |
| US5714344A (en) * | 1993-04-07 | 1998-02-03 | Georgetown University | Protease-derivatized CVF |
| WO1996007738A2 (en) * | 1994-09-08 | 1996-03-14 | Imutran Limited | Modified human c3 proteins |
| US6221657B1 (en) * | 1995-09-08 | 2001-04-24 | Imutran Limited | Modified human C3 DNA sequences and vectors |
| US5922320A (en) * | 1996-06-14 | 1999-07-13 | Georgetown University | Recombinant proCVF |
| WO2005003159A1 (en) * | 2003-07-03 | 2005-01-13 | Koeln Johanna | Complement depletion using recombinant human c3-derivatives |
| US8632780B2 (en) * | 2004-04-30 | 2014-01-21 | University Of Hawaii | Human complement C3 derivates with cobra venom factor-like function |
| US20100179092A1 (en) * | 2006-11-15 | 2010-07-15 | Fritzinger David C | Human complement c3 derivatives with cobra venom factor-like function |
-
2005
- 2005-04-29 US US11/579,235 patent/US8632780B2/en active Active
- 2005-04-29 WO PCT/US2005/015119 patent/WO2005107785A2/en not_active Ceased
- 2005-04-29 KR KR1020067025253A patent/KR20070036057A/ko not_active Ceased
- 2005-04-29 JP JP2007511077A patent/JP2008502323A/ja active Pending
- 2005-04-29 AU AU2005240096A patent/AU2005240096A1/en not_active Abandoned
- 2005-04-29 CA CA002565227A patent/CA2565227A1/en not_active Abandoned
- 2005-04-29 EP EP05743027A patent/EP1755658A4/en not_active Withdrawn
- 2005-04-29 MX MXPA06012321A patent/MXPA06012321A/es not_active Application Discontinuation
-
2006
- 2006-10-26 IL IL178905A patent/IL178905A0/en unknown
-
2007
- 2007-08-07 US US11/890,900 patent/US20080234191A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017519049A (ja) * | 2014-06-12 | 2017-07-13 | ユニヴァーシティ オブ ハワイＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｈａｗａｉｉ | 免疫原性を低減するかまたは予防するためのヒト化コブラ毒因子の使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2565227A1 (en) | 2005-11-17 |
| US8632780B2 (en) | 2014-01-21 |
| US20080311132A1 (en) | 2008-12-18 |
| WO2005107785A3 (en) | 2005-12-15 |
| EP1755658A2 (en) | 2007-02-28 |
| WO2005107785A2 (en) | 2005-11-17 |
| MXPA06012321A (es) | 2007-04-19 |
| US20080234191A1 (en) | 2008-09-25 |
| IL178905A0 (en) | 2007-03-08 |
| AU2005240096A1 (en) | 2005-11-17 |
| EP1755658A4 (en) | 2008-11-05 |
| KR20070036057A (ko) | 2007-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080234191A1 (en) | Human complement C3 derivates with cobra venom factor-like function | |
| JP5833448B2 (ja) | セリンプロテアーゼ誘導体および血液凝固疾患の予防または処置における使用 | |
| CZ302303B6 (cs) | Homodimerní fúzní protein vykazující inhibicní aktivitu na angiogenezi, zpusob jeho produkce, molekula DNA a replikovatelný expresní vektor | |
| HU218408B (hu) | Eljárás protein C- származékok előállítására | |
| JP6884134B2 (ja) | 良性前立腺過形成の患者における手術の必要性を低減する方法 | |
| JP2001061479A (ja) | 血液凝固第ｖｉｉ因子改変体 | |
| JP4855627B2 (ja) | 医薬用途のためのトロンボモジュリン | |
| SK29697A3 (en) | Modified human c3 proteins | |
| JP2004105188A (ja) | プロテアーゼ−耐性トロンボモジュリン・アナログ | |
| Vogel et al. | Cobra venom factor: the unique component of cobra venom that activates the complement system | |
| JP2003313199A (ja) | コラーゲン誘発血小板凝集抑制剤 | |
| EP1088069B1 (en) | Angiostatin-binding protein | |
| JP2003500041A (ja) | Ｍｅｔｈ１およびｍｅｔｈ２ポリヌクレオチドおよびポリペプチド | |
| US20030207348A1 (en) | Polypeptides and polynucleotides encoding same | |
| JPWO1999014325A1 (ja) | 新規Ｆａｓリガンド誘導体 | |
| WO1999014325A1 (fr) | NOUVEAU DERIVE DU LIGAND Fas | |
| SK121798A3 (en) | Native protein of a complement line, a fragment or variant of protein, dna sequence coding a protein, dna construct, a conjugate containing protein, pharmaceutical composition and use of protein | |
| JPH08511157A (ja) | Ｘａファクター阻害活性を有する新規ポリペプチド | |
| US6835381B1 (en) | Methods for modulating angiogenesis by using the anti-angiogenic angiotensin-7 and polynucleotides encoding therefor | |
| CN101014362A (zh) | 具眼镜蛇毒因子样功能的人补体c3衍生物 | |
| JP2005518801A (ja) | 組換えプロテインｃバリアント | |
| CN100425695C (zh) | 新型人Rab GTP酶，其编码序列及用途 | |
| US6908898B1 (en) | Angiogenesis related molecules | |
| US20050244868A1 (en) | Ten-M3 polypeptides and polynucleotides and their methods of use | |
| WO2001000664A2 (en) | Secreted alpha-helical protein-36 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080404 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080404 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110330 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110614 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110621 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110926 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120123 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120621 |